Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Roncolato FT, O'Connell RL, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler MR, King MT, Friedlander ML.

Gynecol Oncol. 2020 Jan;156(1):45-53. doi: 10.1016/j.ygyno.2019.10.001. Epub 2019 Dec 10.

PMID:
31836184
2.

Rapid and sustained airway control in metastatic malignant melanoma: a case report.

Cullivan S, Bruzzi J, McHale T, Shatwan R, Donnellan P, Breen DP.

ERJ Open Res. 2019 Dec 2;5(4). pii: 00050-2019. doi: 10.1183/23120541.00050-2019. eCollection 2019 Oct.

3.

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.

Gullo G, J Eustace A, Canonici A, M Collins D, Kennedy MJ, Grogan L, Breathhnach O, McCaffrey J, Keane M, Martin MJ, Gupta R, Leonard G, O'Connor M, Calvert PM, Donnellan P, Walshe J, McDermott E, Scott K, Hernando A, Parker I, W Murray D, C O'Farrell A, Maratha A, Dicker P, Rafferty M, Murphy V, O'Donovan N, M Gallagher W, Ky B, Tryfonopoulos D, Moulton B, T Byrne A, Crown J.

Ther Adv Med Oncol. 2019 Jul 24;11:1758835919864236. doi: 10.1177/1758835919864236. eCollection 2019.

4.

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.

Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.

PMID:
29248998
5.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).

Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M.

Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26.

PMID:
29107348
6.

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.

Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group.

Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047. Epub 2017 Jun 8.

7.

The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.

Daly LE, Power DG, O'Reilly Á, Donnellan P, Cushen SJ, O'Sullivan K, Twomey M, Woodlock DP, Redmond HP, Ryan AM.

Br J Cancer. 2017 Jan;116(3):310-317. doi: 10.1038/bjc.2016.431. Epub 2017 Jan 10.

8.

An assessment of histological margins and recurrence of melanoma in situ.

Joyce KM, Joyce CW, Jones DM, Donnellan P, Hussey AJ, Regan PJ, Kelly JL.

Plast Reconstr Surg Glob Open. 2015 Mar 6;3(2):e301. doi: 10.1097/GOX.0000000000000272. eCollection 2015 Feb.

9.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
10.

Thrombolysis and iliofemoral vein stent placement in cancer patients with lower extremity swelling attributed to lymphedema.

O'Sullivan GJ, Waldron D, Mannion E, Keane M, Donnellan PP.

J Vasc Interv Radiol. 2015 Jan;26(1):39-45. doi: 10.1016/j.jvir.2014.10.010.

PMID:
25541444
11.

A review of sentinel lymph node biopsy for thin melanoma.

Joyce KM, McInerney NM, Joyce CW, Jones DM, Hussey AJ, Donnellan P, Kerin MJ, Kelly JL, Regan PJ.

Ir J Med Sci. 2015 Mar;184(1):119-23. doi: 10.1007/s11845-014-1221-1. Epub 2014 Nov 1. Review.

PMID:
25366817
12.

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS.

Cancer Med. 2014 Dec;3(6):1517-26. doi: 10.1002/cam4.302. Epub 2014 Jul 18.

13.

Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.

Mannion E, Gilmartin JJ, Donnellan P, Keane M, Waldron D.

Support Care Cancer. 2014 May;22(5):1417-28. doi: 10.1007/s00520-014-2148-9. Epub 2014 Feb 22. Review.

PMID:
24563068
14.

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.

Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS.

Int J Oncol. 2014 Jan;44(1):5-16. doi: 10.3892/ijo.2013.2181. Epub 2013 Nov 15.

15.

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N.

J Clin Oncol. 2013 Sep 10;31(26):3197-204. doi: 10.1200/JCO.2012.48.1275. Epub 2013 Aug 12.

16.

Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.

Fennell DA, McDowell C, Busacca S, Webb G, Moulton B, Cakana A, O'Byrne KJ, Meerbeeck JV, Donnellan P, McCaffrey J, Baas P.

J Thorac Oncol. 2012 Sep;7(9):1466-70.

17.

Identification of a novel endoplasmic reticulum export motif within the eighth α-helical domain (α-H8) of the human prostacyclin receptor.

Donnellan PD, Kimbembe CC, Reid HM, Kinsella BT.

Biochim Biophys Acta. 2011 Apr;1808(4):1202-18. doi: 10.1016/j.bbamem.2011.01.003. Epub 2011 Jan 9.

19.

Scrotal metastases from colorectal carcinoma: a case report.

McWeeney DM, Martin ST, Ryan RS, Tobbia IN, Donnellan PP, Barry KM.

Cases J. 2009 Jan 31;2(1):111. doi: 10.1186/1757-1626-2-111.

20.

Evaluation of carboplatin dosage based on 4-variable modification of diet in renal disease equation.

Barry A, O'Cearbhaill R, Griffin D, Donnellan P, Keane M, Grimes H.

Ir J Med Sci. 2009 Sep;178(3):301-7. doi: 10.1007/s11845-008-0250-z. Epub 2008 Nov 11.

PMID:
19002550
21.

A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma.

Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG.

Melanoma Res. 2003 Aug;13(4):389-93.

PMID:
12883365
22.

Odynorgasmia.

Donnellan P, Breathnach O, Crown JP.

Scand J Urol Nephrol. 2001 Apr;35(2):158.

PMID:
11411663
23.

Aromatase inhibitors and arthralgia.

Donnellan PP, Douglas SL, Cameron DA, Leonard RC.

J Clin Oncol. 2001 May 15;19(10):2767. No abstract available.

PMID:
11352973
24.

Informed consent and randomised controlled trials.

Donnellan P, Smyth J.

J R Coll Surg Edinb. 2001 Apr;46(2):100-2. Review.

PMID:
11329735
25.

Cytomegalovirus pneumonia in a patient with breast cancer on chemotherapy: case report and review of the literature.

Breathnach O, Donnellan P, Collins D, McNicholas W, Crown J.

Ann Oncol. 1999 Apr;10(4):461-5. Review.

26.

New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer.

Donnellan P, Armstrong J, Rowan S, Fennelly D, Lynch V, McDonnell T, McNicholas W, Crown J.

Semin Oncol. 1998 Jun;25(3 Suppl 8):20-3.

PMID:
9704672
28.

Breast cancer and pregnancy.

Daly PA, Donnellan P.

Ir Med J. 1992 Dec;85(4):128-30.

PMID:
1473943

Supplemental Content

Loading ...
Support Center